Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease
Background: Evidence suggests that triple therapy for patients with chronic obstructive pulmonary disease (COPD) is being used in a broader range of patients than recommended by guidelines, which may have health and cost implications. Objective: To explore the relationship between national health te...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2021.1929757 |
| _version_ | 1797231077955207168 |
|---|---|
| author | Jennifer Cook Chloe Bloom Jen Lewis Zoe Marjenberg Jaime Hernando Platz Sue Langham |
| author_facet | Jennifer Cook Chloe Bloom Jen Lewis Zoe Marjenberg Jaime Hernando Platz Sue Langham |
| author_sort | Jennifer Cook |
| collection | DOAJ |
| description | Background: Evidence suggests that triple therapy for patients with chronic obstructive pulmonary disease (COPD) is being used in a broader range of patients than recommended by guidelines, which may have health and cost implications. Objective: To explore the relationship between national health technology assessment (HTA) agency appraisals and market penetration of two fixed-dose combination (FDC) triple therapies. Study design: HTAs from Q3 2017 to Q1 2020 from 10 countries were evaluated. Intervention: Glycopyrronium bromide/formoterol fumarate/beclomethasone (Trimbow®) and umeclidinium/vilanterol/fluticasone furoate (Trelegy™ Ellipta®). Main outcome measure: HTA restrictions and prescribing rates (days of therapy). Results: Seven countries (70%) imposed restrictions on use including prescription only for patients stable on free-combination triple therapy or not controlled on dual therapy, requirement of a specialist prescription or therapeutic plan, prescription only for patients with severe COPD, and use as second-line therapy or later. In general, countries that have imposed restrictions on the use of FDC triple therapies have seen a lower than average uptake. Conclusion: Payer guidance on prescribing FDC triple therapy may potentially support more appropriate prescribing in line with clinical guidelines. It is important for payers to consider which restrictions would ensure the most efficient use of scarce resources. |
| first_indexed | 2024-04-24T15:38:39Z |
| format | Article |
| id | doaj.art-4d8762b3aee14aebab792d1e652fad73 |
| institution | Directory Open Access Journal |
| issn | 2001-6689 |
| language | English |
| last_indexed | 2024-04-24T15:38:39Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj.art-4d8762b3aee14aebab792d1e652fad732024-04-02T00:57:30ZengMDPI AGJournal of Market Access & Health Policy2001-66892021-01-019110.1080/20016689.2021.19297571929757Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary diseaseJennifer Cook0Chloe Bloom1Jen Lewis2Zoe Marjenberg3Jaime Hernando Platz4Sue Langham5Boehringer Ingelheim GmbH, Ingelheim Am RheinNational Heart & Lung Institute, Imperial College LondonMaverex LimitedMaverex LimitedBoehringer Ingelheim GmbH, Ingelheim Am RheinMaverex LimitedBackground: Evidence suggests that triple therapy for patients with chronic obstructive pulmonary disease (COPD) is being used in a broader range of patients than recommended by guidelines, which may have health and cost implications. Objective: To explore the relationship between national health technology assessment (HTA) agency appraisals and market penetration of two fixed-dose combination (FDC) triple therapies. Study design: HTAs from Q3 2017 to Q1 2020 from 10 countries were evaluated. Intervention: Glycopyrronium bromide/formoterol fumarate/beclomethasone (Trimbow®) and umeclidinium/vilanterol/fluticasone furoate (Trelegy™ Ellipta®). Main outcome measure: HTA restrictions and prescribing rates (days of therapy). Results: Seven countries (70%) imposed restrictions on use including prescription only for patients stable on free-combination triple therapy or not controlled on dual therapy, requirement of a specialist prescription or therapeutic plan, prescription only for patients with severe COPD, and use as second-line therapy or later. In general, countries that have imposed restrictions on the use of FDC triple therapies have seen a lower than average uptake. Conclusion: Payer guidance on prescribing FDC triple therapy may potentially support more appropriate prescribing in line with clinical guidelines. It is important for payers to consider which restrictions would ensure the most efficient use of scarce resources.http://dx.doi.org/10.1080/20016689.2021.1929757chronic obstructive pulmonary diseasefixed-dose combinationhealth technology assessmenttriple therapy |
| spellingShingle | Jennifer Cook Chloe Bloom Jen Lewis Zoe Marjenberg Jaime Hernando Platz Sue Langham Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease Journal of Market Access & Health Policy chronic obstructive pulmonary disease fixed-dose combination health technology assessment triple therapy |
| title | Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease |
| title_full | Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease |
| title_fullStr | Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease |
| title_full_unstemmed | Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease |
| title_short | Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease |
| title_sort | impact of health technology assessment on prescribing patterns of inhaled fixed dose combination triple therapy in chronic obstructive pulmonary disease |
| topic | chronic obstructive pulmonary disease fixed-dose combination health technology assessment triple therapy |
| url | http://dx.doi.org/10.1080/20016689.2021.1929757 |
| work_keys_str_mv | AT jennifercook impactofhealthtechnologyassessmentonprescribingpatternsofinhaledfixeddosecombinationtripletherapyinchronicobstructivepulmonarydisease AT chloebloom impactofhealthtechnologyassessmentonprescribingpatternsofinhaledfixeddosecombinationtripletherapyinchronicobstructivepulmonarydisease AT jenlewis impactofhealthtechnologyassessmentonprescribingpatternsofinhaledfixeddosecombinationtripletherapyinchronicobstructivepulmonarydisease AT zoemarjenberg impactofhealthtechnologyassessmentonprescribingpatternsofinhaledfixeddosecombinationtripletherapyinchronicobstructivepulmonarydisease AT jaimehernandoplatz impactofhealthtechnologyassessmentonprescribingpatternsofinhaledfixeddosecombinationtripletherapyinchronicobstructivepulmonarydisease AT suelangham impactofhealthtechnologyassessmentonprescribingpatternsofinhaledfixeddosecombinationtripletherapyinchronicobstructivepulmonarydisease |